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Abstract
Background: Reliable and timely detection of acute rejection in renal transplant patients is important to preserve
the allograft function and to prevent premature allograft failure. The current gold standard for the rejection
diagnosis is an allograft biopsy which is usually performed upon an unexplained decline in allograft function.
Because of the invasiveness of the biopsy, non-invasive tests have been suggested to diagnose acute rejection
including mass spectrometry analysis of urine samples.
Design and methods: The aim of this study is to examine the diagnostic accuracy of mass spectrometry analysis
in urine for the diagnosis of acute rejections using the biopsy as gold-standard. The study is an ongoing prospective,
single-arm, multicentre, phase 3 diagnostic accuracy study. It started in October 2011 and will be concluded in
December 2015. Patient within the first year after transplantation who are scheduled for a biopsy to clarify unexplained
impairment of the allograft are consecutively recruited into the study. The overall sample size (n = 600) was calculated
to demonstrate a sensitivity of 83 % and a specificity of 70 % for a one-sided type one error of 2.5 % and a power of
80 % per hypothesis. Biopsy evaluation and mass spectrometry analysis of urine samples (obtained immediately before
biopsy) are performed independently by different readers without knowledge from the respective other assessment.
The follow-up observation period is 6 months. For the primary analysis, the lower limits of the two-sided 95 %
Wald confidence intervals for sensitivity and specificity will be compared with the pre-specified thresholds
(83 % for sensitivity and 70 % for specificity). In secondary analyses the predictive values, the diagnostic
measures in subgroups, and the clinical course will be assessed.
Discussion: Previous phase 2 diagnostic accuracy studies (in small selected study populations) provided
sufficient evidence to suggest mass spectrometry on urine samples as a promising approach to detect
acute rejections. This study determines the diagnostic performance of the test in the routine setting of
post-transplant patient care, compared to the biopsy-based rejection diagnosis. The next step would be a
randomized trial to compare the two diagnostic strategies (including the urine test or not) in relation to
patient relevant endpoints.
Trial registration: NCT01315067; March 14, 2011
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Background
Acute rejection is an important factor that determines
the long-term function and survival of the renal allo-
graft. Therefore, timely detection and appropriate
treatment of acute rejections is an important objective
in the post-transplant care. Approximately 15-30 % of
the transplanted patients suffer from one or multiple
episodes of acute rejection which occur mainly in the
first year of transplantation [1]. The most common
type of acute rejection − with more than 90 % − is the
T-cell mediated tubulointerstitial rejection (Ia and Ib
according to BANFF classification). Acute T-cell medi-
ated vascular rejection and acute humoral rejection
are less frequent in the first transplant year [2, 3].
The detection of acute rejection in an early stage is
challenging [4]. The current standard in the allograft
surveillance relies on regular monitoring for increases in
serum creatinine or a decrease in creatinine clearance
which then triggers subsequent biopsy. This implies that
acute rejections are diagnosed at a stage where the mor-
phological damage already has led to a relevant functional
impairment of the graft. Because of this problem some
transplant centres perform protocol biopsies as part of the
post-transplant care which can detect acute rejections at
an early subclinical stage before functional impairment
has occurred. However, biopsies are invasive and even
with frequent regular protocol biopsies rejection episodes
may be missed.
Therefore, many attempts have been made to develop
non-invasive tests in blood or urine which are able to
detect acute rejection. Most of these approaches used
single markers or combinations of a few markers.
Mostly due to lacking specificity and sensitivity of these
markers, none of these tests are established in the clinical
routine and post-transplant care of the patients [4]. An
alternative approach, which takes in account the hetero-
geneity of the rejection process, is the use of multiple
markers as detected by mass spectrometry in urinary
samples.
A few diagnostic phase 1 and phase 2 studies with
such non-invasive blood and urine tests (according to
[5, 6]) demonstrated promising results regarding sen-
sitivity and specificity for the diagnosis of rejection
[7–12]. However, until now the validation of these
approaches in a representative study population and
in the clinical routine of the post-transplant is still
missing thus prohibiting a realistic estimation of sen-
sitivity and specificity of these tests.
Beside the small sample sizes in these studies there are
some further limitations. The histological scoring among
the different studies is not uniformly conducted according
to the BANFF classification [7, 9]. Partially, histological
confirmation of the absence of rejection in the test-negative
patients is missing (leading to the so called differential
verification bias). Another important limitation is that, due
to the small sample sizes, effects of potential confounders,
like infectious conditions or different immunosuppressive
regimens, are unknown.
Extending our proof-of concept study on 26 patients
with acute tubulointerstitial rejection [10], we started out
to refine and standardize the sample processing and ana-
lysis [13]. The resulting peptide pattern was validated in a
cohort of 25 patients with and 43 patients without rejec-
tion. The AUC value was calculated to be 0.89 (95 % CI:
0.80 – 0.95). In a replication with a blinded test set of 17
independent patients, 6 of 7 patients with acute rejection
were correctly classified as having rejection and 10 of 11
samples were correctly classified as negative for rejection
(AUC: 0.83; 95 % CI: 0.57-0.96).
Moreover, we were able to identify the sequences of
four peptides of the rejection pattern and found that
three are fragments of the collagen type I alpha(I) (Col
1A1) whereas the other is collagen type I alpha(III)
derived. Similar results with changes of Col1A1 frag-
ments in acute renal allograft rejection have been
reported very recently [12]. In our peptide pattern,
two of the Col1A1 fragments were less abundant in
the rejection samples and one was increased. Aligning
these fragments to other, commonly found Col1A1
peptides in the urine samples, we found that the
increased peptide (ID-114633) possess a PGP motif at
the c-terminal end which is indicative of increased matrix
degradation by MMP-8 and MMP-9. Double-stains of
the biopsies for MMP-8 and for an endothelial cell
marker revealed confinement of MMP-8 to polymorpho-
nuclear leukocytes located within pertubular capillaries
and sparsely, in the interstitial infiltrates and glomerular
capillaries of biopsies with rejection [13].
Given all these facts, sufficient evidence exists to
suggest mass spectrometry on urine samples as a prom-
ising approach to detect acute rejection. However, proof
is lacking that this test provides good diagnostic per-
formance in the routine setting of the post-transplant
patient care, compared to the biopsy-based rejection
diagnosis.
Therefore, the aim of this multicentre prospective
phase 3 diagnostic accuracy study is to investigate if the
mass spectrometry (MS) test developed by Metzger et
al. [13], is useful in a representative setting of the clin-
ical routine post-transplant care. Meticulous collection
of clinical data including potential confounders and use
of rigorous histological standards (BANFF classification,
repeat central pathology reading of biopsies) in this
trial will maximize the interpretation of the obtained
mass spectrometric results. At the end, reliable estima-
tors of the diagnostic accuracy (sensitivity, specificity,
predictive value, limits of the test) will be derived from
the trial.
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Methods/Design
Study aims and objectives
The aim of the study is to prove that the MS test has
good diagnostic performance compared to the allograft
biopsy to detect acute tubulointerstitial rejection in
renal-transplant patients who undergo a biopsy for un-
explained renal dysfunction.
The primary objective of the trial is to show that mass
spectrometry is not relevantly inferior to the gold-standard
allograft biopsy regarding sensitivity and specificity.
The secondary objectives are to evaluate the predictive
values of the MS test and to investigate the diagnostic
accuracy of the MS test in subgroups, namely in patients
with different histological severity of the rejection, with
different severity of functional impairment, with kidney
versus a combined kidney/pancreas transplant, with po-
tential confounders present (e.g. urinary tract infection,
concurrent CMV infection, polyomavirus nephropathy),
and in patients from different study centres.
Study design
This study is a prospective multicentre phase 3 diag-
nostic accuracy study (according to [5, 6]) for the
intra-individual comparison of the MS test and the
allograft biopsy. The MS test is the index test, while the
allograft biopsy is the gold standard. Biopsy and mass
spectrometry will be performed independently by different
readers without knowledge from the respective other
assessment. Results of the MS test will be kept concealed
until the end of the study. Accordingly, this is a non-
interventional trial because the treatment is guided by the
result of the allograft biopsy, as the current diagnostic
standard. All treatments are permitted which are deemed
necessary by the clinicians caring for the patients.
Study setting and period
This study is carried out in 10 German university and
non-university transplant centres: Hannover, Aachen,
Jena, Erlangen, Freiburg, Essen, München, Köln, Berlin,
Hannoversch Münden. It is expected that virtually all
patients who are scheduled for an indicated biopsy
agree to participate in the study because of the non-
interventional nature of the trial. Drop-out rate will be
negligible for primary analysis because once a patient
has consented to participate in the study the essential
data set is available for analysis.
Data collection was initiated in October 2011 and the
conclusion of this study is scheduled for December
2015.
Participants/eligibility criteria
The test should be applicable to all kidney or kidney/
pancreas transplant patients in the post-transplant care
which are scheduled for an indicated biopsy to verify
clinical symptoms of an acute rejection. Therefore, inclu-
sion/exclusion criteria are set out to the least limitations
that are necessary to perform the study meaningfully, i.e.
availability of the results of the comparator ‘renal allograft
biopsy’. The inclusion of patients within the first year of
transplantation is based on the fact that acute rejections
are most frequent in this period. Thus, this population is
suitable for estimation of sensitivity and specificity with
high accuracy. Furthermore for this population the test
would have the greatest relevance.
The inclusion criteria imply that female and male
patients are likewise studied. As this study is carried
out in the setting of adult renal allograft recipient
post-transplant care, results will be applicable to all
adult patients. Enrolment to the study is only allowed
once for each patient, i.e. patients with repeated
episodes of suspected acute rejection are not included
a second time.
Recruitment, procedures and follow-up
After identification of a patient with unexplained allo-
graft function decline (within the first year after trans-
plantation) and the clinical decision to perform a biopsy,
informed consent is obtained from the patient to use an
urine sample from the day of biopsy and the clinical data
for the study.
The urine specimen is obtained immediately before
the biopsy as a spot sample. Mass spectrometry is per-
formed on this sample, along with the usual clinical
routine determinations (protein concentration and
sediment analysis).
The follow-up observation period after acquisition of
the sample is 6 months. Main parameters to be used
from the follow-up period are changes in renal allograft
function (calculated GFR at 6 months after the biopsy in
relation to the GFR before and at the time of biopsy)
and further acute rejection episodes. For the assessment
of allograft function 6 months after inclusion in the
study, a regular out-patient visit will be scheduled for
this time point. If the follow-up visit is impossible, all
efforts will be made to obtain the necessary information
from the primary care physician of the patient.
For the illustration of the trial flow see Fig. 1.
Index test
The index test uses CE-MS technology. Compared with
other spectrometric and spectroscopic technologies, i.e.,
SELDI, NMR, the CE-MS technology offers a wider and
more adjustable measurement range which is particularly
suited for peptides and small proteins of approximately 9
to 180 amino acids in length. Thus, this technology is
more sensitive for the detection of peptides in complex
sample matrices (~1 fmol). It facilitates a higher degree of
throughput (<1 h per sample) and automation (on-line
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coupling of CE and MS data acquisition via contact-close
relays).
For the index test ‘acute rejection diagnosis by CE-MS’
neither internationally accepted pre-defined peptides for
the rejection diagnosis, nor units, cut-offs or categories
are available.
Classification of patient samples with the rejection
pattern is expressed as membership probability and
quantified by the Euclidean distance of the data point
to the maximal margin of a separation hyperplane be-
tween cases and controls in a multidimensional space
constructed by the peptide classifiers (by the use of
Support Vector Machines, SVM). Membership prob-
ability therefore expresses the degree of similarity of a
patients’ peptide profile to the one that was identified
to be specific for the disease in the discovery phase on
histomorphologically well-defined patients.
Test results of the samples will be classified into the
categories ‘rejection’ and ‘no rejection’ by the pre-specified
urinary peptide patterns and algorithms at the cut-off
point of −0.25 based on the evaluation of CE-MS profiles
of patients included in the proof-of-concept study.
Standard of truth
The true disease state is assessed by biopsy according to
the established BANFF criteria because this is the only
accepted standard of truth for acute rejection diagnosis.
This standard of truth is used throughout all relevant
clinical trials and in the clinical routine to diagnose or to
rule out acute rejection in renal transplant patients [14].
It is conceivable that the mass spectrometry test may
detect acute rejections that are missed by biopsy because
of the focal nature of the rejection in the allograft or
because of potential biopsy sampling errors. Therefore, a
sensitivity analysis will be performed secondarily for the
cases with a positive mass spectrometry result and a
negative biopsy, by using the clinical course and subse-
quently performed biopsies (if available) for an assess-
ment of the probable true disease state at the time of
first diagnosis.
Clinical data
Clinical data include demographics of recipient and
donor, immunologic parameters like HLA match and
pre-formed antibodies, calculated GFR at the time of
biopsy, any relevant diagnoses of the allograft like hydro-
nephrosis or delayed graft function, any relevant factors
at the time of biopsy which are potential confounders
of the mass spectrometry test. These include CMV and
polyomavirus infection, urinary tract infection, diabetes
mellitus, hypertension, and the patient’s medication and
immunosuppressive therapy.
Outcome measures
The co-primary outcomes are sensitivity and specificity
of the marker set for the diagnosis of acute rejection in
the whole study population to determine the diagnostic
accuracy of the marker set. These measures definitely
determine whether the performance of the index test is
sufficient to be used for the acute rejection diagnosis in
comparison to the gold standard ‘renal allograft biopsy’.
Key secondary outcomes are (i) predictive values in
terms of acute rejection in the whole study population
and (ii) sensitivity, specificity and predictive values in
subgroups. The subgroup analysis will help to determine
the limits of the index test. This refers particularly to
Fig. 1 Trial flow (including pre-study steps)
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effects of confounding factors or conditions on the per-
formance of the test and to the question which types
and severity grades of acute rejection (in histological and
functional terms) are detected with confidence.
Statistical issues
Sample size
The primary objective of the trial is to show that mass
spectrometry is not relevantly inferior to the gold-
standard allograft biopsy. The null hypothesis of the
study is that sensitivity and specificity of mass spec-
trometry are relevantly reduced compared to the gold
standard biopsy. Thresholds are set to 83 % for sensitiv-
ity and to 70 % for specificity. Sample size calculation
was done with nQuery 4.0, separately for sensitivity and
specificity. The pre-test probability of acute rejection in
kidney or kidney/pancreas transplanted patients with
indication biopsy is expected to be 25 % (Hannover
Transplant Centre Data; unpublished). The estimators of
the test set of the previous phase II study are 91 % for
sensitivity and 76 % for specificity. For both sample size
calculations a one-sided χ2-test for single-proportion is
used, assuming a one-sided type one error of 2.5 % and
setting the power to 80 %. For a sensitivity of 83 % under
the assumption of a true sensitivity of 91 %, 150 patients
with acute rejection are needed, for a specificity of 70 %
under the assumption of a true specificity of 76 %, 440
patients without acute rejection are needed. So, assuming
the pre-test probability of 25 %, in sum a total sample size
of 600 patients should be sufficient, where the patients
with acute rejection (150 as 25 % of 600) determine the
overall required number of patients.
No adjustment for multiplicity is necessary for testing
sensitivity and specificity because both hypotheses have
to be rejected, if the study should be evaluated as suc-
cess. Loss to follow-up will not affect the analysis of
primary and secondary outcomes because all necessary
data for these calculations are collected at the time of
urine sampling and renal biopsy on day 1 of the study.
Methods against bias
Biopsy and mass spectrometry will be performed inde-
pendently by different readers. Readings must have
reference to the medical history of the patients, but
diligence will be exercised that knowledge of the results
of the other test is withheld. For this reason, results of
the experimental test will not be provided for patients
and examiners that perform the gold standard test until
the end of the study.
In addition to the local biopsy reading in each centre,
biopsies will be re-evaluated centrally to confirm the
interpretation of the biopsy. The index test is con-
ducted according to a pre-assigned SOP (for details
see Additional file 1).
Selection bias in the patient recruitment is negligible
because the inclusion and exclusion criteria enable the
study of a representative cohort by consecutively includ-
ing all patients with an indicated biopsy who agree to
participate in the study. The primary analysis will be
confined to the indication biopsy and concomitant urine
sample which were taken at day 1 of the study. Repeated
urine collections from one patient will be not included
into the primary analysis to avoid dependent data in a set-
ting of independent observations from individual patients.
To assess the possible measurement error of the mass
spectrometry, 10 % of the urine samples (randomly chosen)
will be re-run including all sample preparation steps. In the
secondary analysis, the results of these probe pairs will be
used to evaluate the test reproducibility.
Impact of centre on the results will be examined in
the statistical analysis.
Statistical analysis
For the primary analysis, point estimators and two-sided
95 % Wald confidence intervals for sensitivity and speci-
ficity will be calculated. The null hypothesis for sensitivity
will be rejected if the lower bound of the corresponding
confidence interval is above 83 %. The null hypothesis for
specificity will be rejected if the lower bound of the corre-
sponding confidence interval is above 70 %.
For the key secondary analyses, predictive values for
all patients and sensitivity, specificity and predictive
values for subgroups will be analysed descriptively.
Subgroups are: patients with different BANFF grades
of acute rejection; patients with different severity of
acute rejection in terms of functional impairment at
the time of rejection; patients with kidney allografts
alone and patients with combined kidney/pancreas
transplantation; patients from each transplant centre;
patients with concurrent urinary tract infection at the
time of biopsy/urine sampling; patients with concur-
rent CMV infection at the time of biopsy/urine sam-
pling and patients with polyomavirus nephropathy.
Furthermore, the secondary analysis examines whether
certain clinical, laboratory or pathological variables inter-
fere with the mass spectrometric test. This facilitates the
search for potential confounders and the definition of the
limits of the MS test.
For the primary analysis no missing data due to drop-
outs is expected because once a patient has consented to
participate in the study the data for primary analysis is
available. Drop-outs would only affect analysis of follow-
up data (e.g. rejection events after the test).
Within the sensitivity analysis, the clinical course
and subsequently performed biopsies (if available) will
be additionally used for an assessment of the probable
true disease state in case of a positive mass spectrom-
etry result and a negative biopsy. Also, the results of
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the central read of the biopsy vs. the local pathological
diagnosis will be used in the sensitivity analysis.
In a descriptive secondary analysis, the test reproduci-
bility will be evaluated. Therefore, Krippendorff ’s alpha
will be calculated for the probe pairs (of 10 % of the
patients).
Ethical issues
All patients will be asked to consent into the collection
and scientific analysis of urine samples and the clinical
data in an anonymous fashion. Patients will be assured
that the medical treatment will be not influenced by
their decision to participate in the study.
As indicated biopsies are sought to be performed with-
out much delay, the time to consider participation in the
study might be rather short in some instances. There-
fore, patients will be explicitly informed that they can
withdraw their initially given consent.
Financing
The trial is funded by the German research foundation
(DFG) in the context of the clinical trials funding pro-
gram (Non-invasive diagnosis of acute rejection in renal
transplant patients using mass spectrometry of urine
samples - a multicentre diagnostic phase III trial).
Discussion
The perspective is that the MS test (respectively, a
simplified test system derived from this method) could
be used in the regular post-transplant surveillance for
acute rejection, in place of the relatively insensitive
procedure with periodic monitoring of the graft func-
tion by creatinine determinations. The MS test would
serve as a decision help to decide whether an allograft
biopsy is necessary in this setting to confirm the pres-
ence of rejection. In the long-term, the MS test might
even replace some of the biopsies.
For the affected patients this would translate into a more
timely detection of acute rejection and into fewer renal allo-
graft biopsies, including avoidance of procedure-related
complications. If the test proves to be successful in early
and reliably identifying patients with a high probability of
acute rejection, this would enable timely intervention and
probably, prevention of renal tissue injury and of the dele-
terious long-term consequences of the rejection.
Assessing the potential economic impact is premature.
In case, the test could be successfully applied in the
routine post-transplant patient care, reduction in graft
losses/increased graft survival has to be shown in this
setting in a randomized diagnostic phase 4 study [6].
Furthermore, the proposed undertaking offers the unique
perspective to use the well-characterized pool of collected
and analysed samples in a later study to examine potentially
interesting peptides, in an attempt to further delineate im-
portant pathways and processes of the rejection.
Trial status
The study was reviewed by the leading Ethics Committee
of the Medical School Hannover. In accordance with
German law, this ethical approval is sufficient for all par-
ticipating centres, because there is no intervention for the
patients (the diagnostic test is an in-vitro test). The first
patient was enrolled in October 2011. The clinical trial is
ongoing and is expected to be finished in December 2015.
Additional file
Additional file 1: Quality Assurance/Monitoring. (DOC 31 kb)
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